Altered Brain Glucose Consumption in Cogan’s Syndrome
Purpose. Prospective, controlled cohort study to investigate possible alterations in brain glucose metabolism (CMRglc) in patients with Cogan’s syndrome (CS). Patients and Methods. Functional mapping of the CMRglc was obtained by quantitative molecular imaging positron emission tomography, combined...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2016/3207150 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548150582181888 |
|---|---|
| author | Paolo Mora Livia Ruffini Caterina Ghetti Stella Ghirardini Maura Scarlattei Giorgio Baldari Carla Cidda Pierangela Rubino Stefano A. Gandolfi Jelka G. Orsoni |
| author_facet | Paolo Mora Livia Ruffini Caterina Ghetti Stella Ghirardini Maura Scarlattei Giorgio Baldari Carla Cidda Pierangela Rubino Stefano A. Gandolfi Jelka G. Orsoni |
| author_sort | Paolo Mora |
| collection | DOAJ |
| description | Purpose. Prospective, controlled cohort study to investigate possible alterations in brain glucose metabolism (CMRglc) in patients with Cogan’s syndrome (CS). Patients and Methods. Functional mapping of the CMRglc was obtained by quantitative molecular imaging positron emission tomography, combined with computed tomography (FDG-PET/CT). The patients were divided into three clinical groups: typical CS; atypical CS (ACS); autoimmune inner ear disease (AIED). The unmatched control group (CG) consisted of subjects requiring FDG-PET/CT for an extracranial pathology. Statistical mapping searched areas of significant glucose hypometabolism in all the affected patients (DG) and in each clinical subgroup. The results were compared with those of the CG. Results. 44 patients were enrolled (DG) and assigned to the three study groups: 8 patients to the CS group; 21 patients to the ACS group; and 15 to the AIED group. Sixteen subjects formed the CG group. Areas of significant brain glucose hypometabolism were identified in all the study groups, with the largest number and extension in the DG and CS. Conclusions. This study revealed areas of significantly altered CMRglc in patients with CS (any subform) without neurologic complains and normal conventional neuroimaging. Our results suggest that FDG-PET/CT may represent a very useful tool for the global assessment of patients with Cogan’s syndrome. |
| format | Article |
| id | doaj-art-bb17aa572b3740a89a16ca6553122a82 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-bb17aa572b3740a89a16ca6553122a822025-02-03T06:42:11ZengWileyJournal of Ophthalmology2090-004X2090-00582016-01-01201610.1155/2016/32071503207150Altered Brain Glucose Consumption in Cogan’s SyndromePaolo Mora0Livia Ruffini1Caterina Ghetti2Stella Ghirardini3Maura Scarlattei4Giorgio Baldari5Carla Cidda6Pierangela Rubino7Stefano A. Gandolfi8Jelka G. Orsoni9Institute of Ophthalmology, University Hospital of Parma, Parma, ItalyNuclear Medicine Unit, University Hospital of Parma, Parma, ItalyMedical Physic Department, University Hospital of Parma, Parma, ItalyInstitute of Ophthalmology, University Hospital of Parma, Parma, ItalyNuclear Medicine Unit, University Hospital of Parma, Parma, ItalyNuclear Medicine Unit, University Hospital of Parma, Parma, ItalyNuclear Medicine Unit, University Hospital of Parma, Parma, ItalyInstitute of Ophthalmology, University Hospital of Parma, Parma, ItalyInstitute of Ophthalmology, University Hospital of Parma, Parma, ItalyInstitute of Ophthalmology, University Hospital of Parma, Parma, ItalyPurpose. Prospective, controlled cohort study to investigate possible alterations in brain glucose metabolism (CMRglc) in patients with Cogan’s syndrome (CS). Patients and Methods. Functional mapping of the CMRglc was obtained by quantitative molecular imaging positron emission tomography, combined with computed tomography (FDG-PET/CT). The patients were divided into three clinical groups: typical CS; atypical CS (ACS); autoimmune inner ear disease (AIED). The unmatched control group (CG) consisted of subjects requiring FDG-PET/CT for an extracranial pathology. Statistical mapping searched areas of significant glucose hypometabolism in all the affected patients (DG) and in each clinical subgroup. The results were compared with those of the CG. Results. 44 patients were enrolled (DG) and assigned to the three study groups: 8 patients to the CS group; 21 patients to the ACS group; and 15 to the AIED group. Sixteen subjects formed the CG group. Areas of significant brain glucose hypometabolism were identified in all the study groups, with the largest number and extension in the DG and CS. Conclusions. This study revealed areas of significantly altered CMRglc in patients with CS (any subform) without neurologic complains and normal conventional neuroimaging. Our results suggest that FDG-PET/CT may represent a very useful tool for the global assessment of patients with Cogan’s syndrome.http://dx.doi.org/10.1155/2016/3207150 |
| spellingShingle | Paolo Mora Livia Ruffini Caterina Ghetti Stella Ghirardini Maura Scarlattei Giorgio Baldari Carla Cidda Pierangela Rubino Stefano A. Gandolfi Jelka G. Orsoni Altered Brain Glucose Consumption in Cogan’s Syndrome Journal of Ophthalmology |
| title | Altered Brain Glucose Consumption in Cogan’s Syndrome |
| title_full | Altered Brain Glucose Consumption in Cogan’s Syndrome |
| title_fullStr | Altered Brain Glucose Consumption in Cogan’s Syndrome |
| title_full_unstemmed | Altered Brain Glucose Consumption in Cogan’s Syndrome |
| title_short | Altered Brain Glucose Consumption in Cogan’s Syndrome |
| title_sort | altered brain glucose consumption in cogan s syndrome |
| url | http://dx.doi.org/10.1155/2016/3207150 |
| work_keys_str_mv | AT paolomora alteredbrainglucoseconsumptionincoganssyndrome AT liviaruffini alteredbrainglucoseconsumptionincoganssyndrome AT caterinaghetti alteredbrainglucoseconsumptionincoganssyndrome AT stellaghirardini alteredbrainglucoseconsumptionincoganssyndrome AT maurascarlattei alteredbrainglucoseconsumptionincoganssyndrome AT giorgiobaldari alteredbrainglucoseconsumptionincoganssyndrome AT carlacidda alteredbrainglucoseconsumptionincoganssyndrome AT pierangelarubino alteredbrainglucoseconsumptionincoganssyndrome AT stefanoagandolfi alteredbrainglucoseconsumptionincoganssyndrome AT jelkagorsoni alteredbrainglucoseconsumptionincoganssyndrome |